• 1. Pyrrolizidine alkaloids quantified in soil and water using UPLC-MS/MS
  Jawameer R. Hama,Bjarne W. Strobel RSC Adv. 2019 9 30350
• 2. The senecio alkaloids. Part XI. The conversion of rosmarinine into senecionine and the general structure of the senecio alkaloids
  M. J. Koekemoer,F. L. Warren J. Chem. Soc. 1955 63
• 3. The senecio alkaloids. Part XI. The conversion of rosmarinine into senecionine and the general structure of the senecio alkaloids
  M. J. Koekemoer,F. L. Warren J. Chem. Soc. 1955 63
• 4. Pyrrolizidine alkaloids
  D. J. Robins Nat. Prod. Rep. 1989 6 577
• 5. 169. Alkaloids of Senecio. Part II. Senecionine and squalidine
  G. Barger,J. J. Blackie J. Chem. Soc. 1936 743

• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Macrolides and analogues Macrolides and analogues
• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Macrolides and analogues

Introduction to Senecionine (CAS No: 130-01-8) and Its Recent Research Applications

Senecionine, a naturally occurring biologically active compound with the chemical formula C₁₅H₁₃NO₂, is identified by its unique Chemical Abstracts Service Number (CAS No: 130-01-8). This alkaloid, primarily derived from the genus Senecio (a family of flowering plants), has garnered significant attention in the field of pharmaceutical chemistry and medicinal research due to its diverse pharmacological properties. The compound's structural complexity and functional groups contribute to its remarkable biological activity, making it a subject of extensive investigation in both academic and industrial settings.

The phytochemical profile of senecionine encompasses a range of bioactive derivatives, each exhibiting distinct therapeutic potential. Recent studies have highlighted the compound's role in anti-inflammatory, antioxidant, and anticancer mechanisms. The molecular interactions between senecionine and biological targets, such as enzymes and receptors, have been extensively analyzed using advanced spectroscopic and computational techniques. These studies not only elucidate the mechanistic pathways but also open avenues for the development of novel drug candidates.

In the realm of clinical research, senecionine has been investigated for its potential in modulating pathways associated with chronic diseases. Notably, preclinical trials have demonstrated its efficacy in reducing inflammation and oxidative stress, which are key pathological processes in conditions like arthritis and neurodegenerative disorders. The compound's ability to selectively interact with specific biomarkers has positioned it as a promising candidate for targeted therapy. Additionally, senecionine's phototoxicity has been explored in photodynamic therapy (PDT), where it acts as a photosensitizer to induce cell death in cancerous tissues.

The synthetic chemistry of senecionine has also seen significant advancements, with researchers developing efficient methodologies for its total synthesis and semi-synthesis. These efforts have not only enhanced the availability of the compound for research purposes but also facilitated structural modifications to improve its pharmacokinetic properties. Techniques such as asymmetric synthesis and biocatalysis have been employed to achieve high enantiomeric purity, which is crucial for therapeutic applications. The integration of these synthetic strategies has paved the way for the development of derivatives with enhanced bioavailability and reduced side effects.

From a computational chemistry perspective, senecionine's interactions with biological targets have been modeled using molecular docking and molecular dynamics simulations. These computational approaches have provided insights into the binding affinities and binding modes of senecionine with proteins such as kinases and transcription factors. Such data is invaluable for designing structure-activity relationship (SAR) studies, which aim to optimize the compound's therapeutic profile. The synergy between experimental and computational methods has accelerated the discovery pipeline for senecionine-based therapeutics.

The regulatory landscape governing the use of senecionine in pharmaceuticals is another critical aspect that has evolved over time. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established guidelines for the safety and efficacy evaluation of compounds like senecionine. Compliance with these regulations ensures that any future drug candidates derived from senecionine meet stringent quality standards before entering clinical trials. This regulatory framework also emphasizes ethical considerations, including patient consent and data integrity in clinical research.

The industrial applications of senecionine extend beyond pharmaceuticals into nutraceuticals and cosmetics. Its bioactive properties make it a suitable ingredient for formulations aimed at promoting health and wellness. Companies specializing in natural products have incorporated senecionine into dietary supplements and skincare products, leveraging its antioxidant and anti-inflammatory benefits. The growing demand for natural-based therapeutics has spurred innovation in extraction and formulation technologies to enhance the stability and efficacy of senecionine-containing products.

In conclusion, senecionine (CAS No: 130-01-8) represents a fascinating compound with multifaceted applications in chemical biology, pharmaceutical development, and industrial biotechnology. The latest research highlights its potential as a therapeutic agent, particularly in addressing chronic inflammatory diseases and cancer. Advances in synthetic chemistry, computational modeling, and regulatory frameworks continue to drive progress in harnessing senecionine's bioactive properties. As our understanding of this compound deepens, so too does its promise as a cornerstone molecule in modern medicine.

• 23506-96-9(2H-[1,6]Dioxacycloundecino[2,3,4-gh]pyrrolizine-2,6(3H)-dione,5-ethyl-4,5,8,10,12,13,13a,13b-octahydro-4,5-dihydroxy-3-(1-methylethyl)-,(3R,4R,5R,13aR,13bR)- (9CI))
• 30000-36-3([1,6]Dioxacyclododecino[2,3,4-gh]pyrrolizine-2,7-dione,6-(acetyloxy)-3-ethyl-3,4,5,6,9,11,13,14,14a,14b-decahydro-3-hydroxy-5,6-dimethyl-,(3R,5R,6S,14aR,14bR)-)
• 10285-06-0((+)-Intermedine)
• 303-34-4(Lasiocarpine)
• 303-33-3(heliotrine)
• 115712-88-4(2H-1a,5-Methano-4H-oxireno[12,13][1,5,10]trioxacyclotetradecino[6,7,8-gh]pyrrolizine-6,15(5H,15aH)-dione,7a,8,9,11,12b,13-hexahydro-5-hydroxy-4,15a-dimethyl-, (7aR,12bR)-)
• 15503-87-4(Usaramine)
• 24916-51-6(Acetylspiramycin)
• 315-22-0(Monocrotaline)
• 13268-67-2(Senecionine N-oxide)